无细胞核和线粒体DNA作为评估败血症严重程度的潜在生物标志物
Felipe Silva de Miranda1,2,3, Livia Maria A M Claudio4, Dayanne Silva M de Almeida1,3
1Department of Biological Science State, University of Santa Cruz, Ilhéus 45662-900, Bahia, Brazil.
Biomedicines
|May 25, 2024
概括
无细胞DNA (cfDNA) 显示出作为败血症生物标志物的前景. 升高的水平与疾病严重程度相关,可以帮助预测重症监护室 (ICU) 的入院,有助于败血症预后.
科学领域:
- 生物标志物 生物标志物
- 分子诊断学 分子诊断
- 关键护理医学 关键护理医学
背景情况:
- 败血症仍然是全球主要的健康问题,需要改进诊断和预后工具.
- 尽管有进展,但准确评估败血症的严重程度和预测患者的结果仍然具有挑战性.
- 无细胞核DNA (cf-nDNA) 和无细胞线粒体DNA (cf-mtDNA) 正在成为各种疾病的潜在指标.
研究的目的:
- 评估cf-nDNA和cf-mtDNA在败血症患者的诊断和预后价值.
- 评估cfDNA水平与败血症严重程度之间的相关性.
- 为了确定cfDNA是否可以预测需要进入重症监护室 (ICU) 的需要.
主要方法:
- 在94名患者的血cfDNA度使用qPCR测量,分为感染,败血症和败血性休克组.
- 分析包括接收器操作特征 (ROC) 曲线,以评估诊断准确性.
- 进行了cf-nDNA与顺序器官衰竭评估 (SOFA) 评分的综合分析.
主要成果:
- 血cfDNA水平随着败血症的严重程度显著增加.
- 生物标志物L1PA290在区分感染和败血症方面表现良好 (AUC=0.817).
- 将cf-nDNA与SOFA得分相结合,改善了预测败血症严重程度和ICU入院的AUC,灵敏度和特异性.
结论:
- 血cfDNA,特别是cf-nDNA,作为评估败血症严重程度的有价值生物标志物.
- cfDNA可以区分感染和败血症,并预测ICU入院,表明其在败血症管理中的潜力.
- 结合cf-nDNA和SOFA得分,可以提高败血症患者的预后准确性.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
769
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769